Analysts warn that a House health reform bill, which would demand drugmakers to offer Medicare and Medicaid patients about $60 billion in drug rebates over a decade, could cost the pharmaceutical industry up to $150 billion over the next 10 years. Ken Johnson, senior vice president of the Pharmaceutical Research and Manufacturers of America, said the mandatory rebate in the proposal would reduce research-and-development spending and result in job cuts.

Full Story:
PharmaTimes (U.K.)

Related Summaries